sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
The result of this meta-analysis suggested a statistically significant association between H. pylori infection and OAG. | The result of this meta-analysis did not suggest a statistically significant association between H. pylori infection and OAG. | -1 |
Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. | Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was higher than that reported from white populations, but early AMD signs were less common among Asians. | -1 |
Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. | There is no evidence that among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. | 0 |
Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. | Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were not less common among Asians. | -1 |
Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. | Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were more common among Asians. | -1 |
Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but early AMD signs were less common among Asians. | Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations, but there is no evidence that early AMD signs were less common among Asians. | 0 |
This meta-analysis showed that SKIV2L rs429608 was statistically associated with AMD and it might exert a protective effect on AMD. | This meta-analysis showed that SKIV2L rs429608 was statistically associated with AMD and it might exert a negative effect on AMD. | -1 |
This meta-analysis showed that SKIV2L rs429608 was statistically associated with AMD and it might exert a protective effect on AMD. | This meta-analysis showed that SKIV2L rs429608 was statistically associated with AMD and it exerts a protective effect on AMD. | 1 |
Our results showed that anti-VEGF agents were superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | Our results showed that anti-VEGF agents were not superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | -1 |
Our results showed that anti-VEGF agents were superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | Our results showed that anti-VEGF agents were inferior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | -1 |
Our results showed that anti-VEGF agents were superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | There is no evidence that anti-VEGF agents were superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | 0 |
Our results showed that anti-VEGF agents were superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | Our results showed that anti-VEGF agents might be superior to placebo in CRVO-ME treatment with no statistically significant AEs, especially in younger people and for ischemic type. | 1 |
This study shows that there was no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. | This study shows that there was an association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. | -1 |
This study shows that there was no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. | This study shows that there may be no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. | 1 |
Based on the included trials, we found no evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. | Based on the included trials, we found evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. | -1 |
Based on the included trials, we found no evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. | Based on the included trials, we found no evidence that antiangiogenic steroids cause visual loss in patients with neovascular AMD. | -1 |
Based on the included trials, we found no evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. | Based on the included trials, we found evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. | 0 |
In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was not significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | -1 |
In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an decreased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | -1 |
In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was not ssociated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | -1 |
In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly increased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). | -1 |
Our findings indicated that rs1801131 and rs1801133 polymorphisms may serve as genetic biomarkers of glaucoma in West Asians. | Our findings indicated that rs1801131 and rs1801133 polymorphisms may not serve as genetic biomarkers of glaucoma in West Asians. | -1 |
Our findings indicated that rs1801131 and rs1801133 polymorphisms may serve as genetic biomarkers of glaucoma in West Asians. | There is no evidence that rs1801131 and rs1801133 polymorphisms may serve as genetic biomarkers of glaucoma in West Asians. | 0 |
Our findings indicated that rs1801131 and rs1801133 polymorphisms may serve as genetic biomarkers of glaucoma in West Asians. | Our findings indicated that rs1801131 and rs1801133 polymorphisms are genetic biomarkers of glaucoma in West Asians. | 1 |
The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. | The rs243865 MMP-2 polymorphism was associated with an increased risk of developing AMD. | -1 |
The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. | The rs243865 MMP-2 polymorphism was not associated with a decreased risk of developing AMD. | -1 |
The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. | There is no evidence that the rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. | 0 |
The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. | The rs243865 MMP-2 polymorphism might not be associated with an increased risk of developing AMD. | 1 |
Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research. | Although one study result indicated no efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research. | -1 |
Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research. | Although there is no evidence of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research. | 0 |
The present meta-analysis suggested that there might be a significant association of GSTM1 null genotype with POAG risk in East Asians. | The present meta-analysis suggested that there might not be a significant association of GSTM1 null genotype with POAG risk in East Asians. | -1 |
The present meta-analysis suggested that there might be a significant association of GSTM1 null genotype with POAG risk in East Asians. | The present meta-analysis suggested that there is a significant association of GSTM1 null genotype with POAG risk in East Asians. | 1 |
Results of this meta-analysis suggest that IVTA is more effective for improving VA in DME. | Results of this meta-analysis suggest that IVTA is not more effective for improving VA in DME. | -1 |
Results of this meta-analysis suggest that IVTA is more effective for improving VA in DME. | Results of this meta-analysis suggest that IVTA is less effective for improving VA in DME. | -1 |
Results of this meta-analysis suggest that IVTA is more effective for improving VA in DME. | There is no evidence that IVTA is more effective for improving VA in DME. | 0 |
Results of this meta-analysis suggest that IVTA is more effective for improving VA in DME. | Results of this meta-analysis suggest that IVTA may be more effective for improving VA in DME. | 1 |
Short-term statin use is associated with a reduced incidence of glaucoma. | Short-term statin use is not associated with a reduced incidence of glaucoma. | -1 |
Short-term statin use is associated with a reduced incidence of glaucoma. | Short-term statin use is associated with am increased incidence of glaucoma. | -1 |
Short-term statin use is associated with a reduced incidence of glaucoma. | There is no evidence that short-term statin use is associated with a reduced incidence of glaucoma. | 0 |
Short-term statin use is associated with a reduced incidence of glaucoma. | Short-term statin use may be associated with a reduced incidence of glaucoma. | 1 |
NPGS augmented with MMC was associated with IOP-lowering efficacy comparable to that of TE plus MMC. | NPGS augmented with MMC was not associated with IOP-lowering efficacy comparable to that of TE plus MMC. | -1 |
NPGS augmented with MMC was associated with IOP-lowering efficacy comparable to that of TE plus MMC. | There is no evidence that NPGS augmented with MMC was associated with IOP-lowering efficacy comparable to that of TE plus MMC. | 0 |
NPGS augmented with MMC was associated with IOP-lowering efficacy comparable to that of TE plus MMC. | NPGS augmented with MMC may be associated with IOP-lowering efficacy comparable to that of TE plus MMC. | 1 |
However, significantly fewer patients achieved the target IOP with NPGS augmented with MMC than with TE plus MMC. | However, significantly less patients achieved the target IOP with NPGS augmented with MMC than with TE plus MMC. | -1 |
NPGS augmented with MMC was better tolerated than TE plus MMC. | NPGS augmented with MMC was not better tolerated than TE plus MMC. | -1 |
NPGS augmented with MMC was better tolerated than TE plus MMC. | NPGS augmented with MMC was tolerated worse than TE plus MMC. | -1 |
NPGS augmented with MMC was better tolerated than TE plus MMC. | There is no evidence that NPGS augmented with MMC was better tolerated than TE plus MMC. | 0 |
NPGS augmented with MMC was better tolerated than TE plus MMC. | NPGS augmented with MMC may be better tolerated than TE plus MMC. | 1 |
Intravitreal bevacizumab injection is effective in improving VA in patients with primary DMO for 6 weeks, but the benefits are no longer present 12 weeks following the injection. | Intravitreal bevacizumab injection may be effective in improving VA in patients with primary DMO for 6 weeks, but the benefits are no longer present 12 weeks following the injection. | 1 |
These values suggest a good overall performance of OCT for diagnosing CSME. | These values suggest a bad overall performance of OCT for diagnosing CSME. | -1 |
These values suggest a good overall performance of OCT for diagnosing CSME. | There is no evidence of good overall performance of OCT for diagnosing CSME. | 0 |
These values suggest a good overall performance of OCT for diagnosing CSME. | These values may suggest a good overall performance of OCT for diagnosing CSME. | 1 |
OCT performs well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | OCT does not perform well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | -1 |
OCT performs well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | OCT performs worse compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | -1 |
OCT performs well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | There is no evidence that OCT performs well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | 0 |
OCT performs well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | OCT may perform well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. | 1 |
The visual acuity outcomes in patients affected by nontractional diabetic macular edema using pars plana vitrectomy with ILM peeling versus no ILM peeling were not significantly different. | The visual acuity outcomes in patients affected by nontractional diabetic macular edema using pars plana vitrectomy with ILM peeling versus no ILM peeling were significantly different. | -1 |
The visual acuity outcomes in patients affected by nontractional diabetic macular edema using pars plana vitrectomy with ILM peeling versus no ILM peeling were not significantly different. | There is no evidence that the visual acuity outcomes in patients affected by nontractional diabetic macular edema using pars plana vitrectomy with ILM peeling versus no ILM peeling were not significantly different. | 0 |
The visual acuity outcomes in patients affected by nontractional diabetic macular edema using pars plana vitrectomy with ILM peeling versus no ILM peeling were not significantly different. | The visual acuity outcomes in patients affected by nontractional diabetic macular edema using pars plana vitrectomy with ILM peeling versus no ILM peeling might not be not significantly different. | 1 |
The results indicate that sunlight exposure may not be associated with increased risk of AMD based on current published data. | The results indicate that sunlight exposure may be associated with increased risk of AMD based on current published data. | -1 |
The results indicate that sunlight exposure may not be associated with increased risk of AMD based on current published data. | The results indicate that sunlight exposure may not be associated with decreased risk of AMD based on current published data. | -1 |
The results indicate that sunlight exposure may not be associated with increased risk of AMD based on current published data. | There is no evidence that sunlight exposure is associated with increased risk of AMD based on current published data. | 0 |
The results indicate that sunlight exposure may not be associated with increased risk of AMD based on current published data. | The results indicate that sunlight exposure is not associated with increased risk of AMD based on current published data. | 1 |
Meta-analysis of existing data showed that rs1799750 may affect individual susceptibility to glaucoma. | Meta-analysis of existing data showed that rs1799750 may not affect individual susceptibility to glaucoma. | -1 |
Meta-analysis of existing data showed that rs1799750 may affect individual susceptibility to glaucoma. | There is no evidence that rs1799750 may affect individual susceptibility to glaucoma. | 0 |
Meta-analysis of existing data showed that rs1799750 may affect individual susceptibility to glaucoma. | Meta-analysis of existing data showed that rs1799750 affects individual susceptibility to glaucoma. | 1 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy did not reduce IOP more nor had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | -1 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could increase IOP more and had lower success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | -1 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | There is no evidence that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | 0 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy may reduce IOP more and have higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | 1 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is not associated with lower postoperative complications. | -1 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with more postoperative complications. | -1 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while there is no evidence that the non-penetrating trabecular surgery is associated with lower postoperative complications. | 0 |
It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery is associated with lower postoperative complications. | It is concluded that, compared with the non-penetrating trabeculectomy, the traditional trabeculectomy could reduce IOP more and had higher success rate while the non-penetrating trabecular surgery may be associated with lower postoperative complications. | 1 |
The results of this study demonstrated the clinical effectiveness of eccentric viewing training for individuals with AMD. This result should be interpreted cautiously, though, given the possibility of publication bias. | The results of this study did not demonstrate the clinical effectiveness of eccentric viewing training for individuals with AMD. This result should be interpreted cautiously, though, given the possibility of publication bias. | -1 |
This meta-analysis does not demonstrate an association between POAG and all-cause or cardiovascular mortality. | This meta-analysis demonstrates an association between POAG and all-cause or cardiovascular mortality. | -1 |
This meta-analysis does not demonstrate an association between POAG and all-cause or cardiovascular mortality. | There is no evidence of an association between POAG and all-cause or cardiovascular mortality. | 0 |
This meta-analysis does not demonstrate an association between POAG and all-cause or cardiovascular mortality. | This meta-analysis may not demonstrate an association between POAG and all-cause or cardiovascular mortality. | 1 |
Our meta-analysis revealed a significantly protective role of ε4 on each subtypes of AMD, but no supportive evidence of the association of ε2 with AMD. | Our meta-analysis revealed a significant association of ε4 with each subtypes of AMD, but no supportive evidence of the association of ε2 with AMD. | -1 |
Our meta-analysis revealed a significantly protective role of ε4 on each subtypes of AMD, but no supportive evidence of the association of ε2 with AMD. | Our meta-analysis revealed a significantly protective role of ε4 on each subtypes of AMD and supportive evidence of the association of ε2 with AMD. | -1 |
Our meta-analysis revealed a significantly protective role of ε4 on each subtypes of AMD, but no supportive evidence of the association of ε2 with AMD. | Our meta-analysis revealed a significantly protective role of ε4 on each subtypes of AMD and supportive evidence of the association of ε2 with AMD. | 0 |
For some patients with DMO, VEGF inhibitors seem to be more effective as a short-term treatment option than alternative therapies. | For some patients with DMO, VEGF inhibitors seem to be not more effective as a short-term treatment option than alternative therapies. | -1 |
For some patients with DMO, VEGF inhibitors seem to be more effective as a short-term treatment option than alternative therapies. | For some patients with DMO, VEGF inhibitors seem to be less effective as a short-term treatment option than alternative therapies. | -1 |
For some patients with DMO, VEGF inhibitors seem to be more effective as a short-term treatment option than alternative therapies. | For some patients with DMO, VEGF inhibitors are more effective as a short-term treatment option than alternative therapies. | 1 |
The evidence is not of sufficient quality to confirm safety. | The evidence is of sufficient quality to confirm safety. | -1 |
The evidence is not of sufficient quality to confirm safety. | The evidence is of insufficient quality to confirm safety. | -1 |
The evidence is not of sufficient quality to confirm safety. | The evidence is of sufficient quality to confirm safety. | 0 |
Based on the strength of AREDS, we can conclude that zinc treatment may be effective in preventing progression to advanced AMD. | Based on the strength of AREDS, we can conclude that zinc treatment may not be effective in preventing progression to advanced AMD. | -1 |
Based on the strength of AREDS, we can conclude that zinc treatment may be effective in preventing progression to advanced AMD. | Based on the strength of AREDS, we can conclude that zinc treatment may be ineffective in preventing progression to advanced AMD. | -1 |
Based on the strength of AREDS, we can conclude that zinc treatment may be effective in preventing progression to advanced AMD. | Based on the strength of AREDS, we can conclude that zinc treatment is effective in preventing progression to advanced AMD. | 1 |
State-of-the-art neural networks could effectively detect clinical significant DR. | State-of-the-art neural networks could not effectively detect clinical significant DR. | -1 |
State-of-the-art neural networks could effectively detect clinical significant DR. | There is no evidence that state-of-the-art neural networks can effectively detect clinical significant DR. | 0 |
State-of-the-art neural networks could effectively detect clinical significant DR. | State-of-the-art neural networks might effectively detect clinical significant DR. | 1 |
PRN treatment resulted in minor but statistically significant decrease in mean BCVA which may not be clinically meaningful. | PRN treatment resulted in minor but statistically significant decrease in mean BCVA which may be clinically meaningful. | -1 |
PRN treatment resulted in minor but statistically significant decrease in mean BCVA which may not be clinically meaningful. | PRN treatment resulted in minor but statistically significant increase in mean BCVA which may not be clinically meaningful. | -1 |
Beneficial effect was also observed in one dexamethasone DDS trial. | Harmful effect was also observed in one dexamethasone DDS trial. | -1 |
RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation may improve visual outcomes in eyes with persistent or refractory DME. | RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation may not improve visual outcomes in eyes with persistent or refractory DME. | -1 |
RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation may improve visual outcomes in eyes with persistent or refractory DME. | RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation may deteriorate visual outcomes in eyes with persistent or refractory DME. | -1 |
RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation may improve visual outcomes in eyes with persistent or refractory DME. | There is no evidence that steroids placed inside the eye by either intravitreal injection or surgical implantation improve visual outcomes in eyes with persistent or refractory DME. | 0 |
RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation may improve visual outcomes in eyes with persistent or refractory DME. | RCTs included in this review suggest that steroids placed inside the eye by either intravitreal injection or surgical implantation improve visual outcomes in eyes with persistent or refractory DME. | 1 |